HealthProves
Home/Fabrikanten/Bryant Ranch Prepack
Fabrikant-profiel

Bryant Ranch Prepack

Farmaceutisch bedrijf88 producten gevolgd
88
producten gevolgd
4.705.846
totaal meldingen
788
recalls geregistreerd
68,5%
ernstig algeheel
Producten
88 van 88 getoond
ProductGoedgekeurdMeldingen ↓Top signaalRecalls
1983393.086hartfalen met longoedeem14
1953374.035sinusitis2
2000359.779Medicijn niet effectief voor goedgekeurde indicatie25
2004267.198Ontwenningssyndroom10
1996243.012diabetes type 265
—195.098chronische nierziekte17
1997188.609diabetes type 212
2007181.371Chemische brandwond van de huid4
1984153.758jicht7
1981133.343Bradycardie5
1995131.745transplantaatafwijzing9
2002129.920serotoninesyndroom11
1993129.795serotoninesyndroom0
2002124.895serotoninesyndroom1
1982112.882multipel myeloom19
—99.522astma1
198395.444Leerstoornis22
199283.951atriumfibrilleren27
195470.807Economisch probleem7
199661.926terugval multiple sclerose4
199660.482terugval multiple sclerose4
199460.122verlaagd bloedglucose14
—60.053atriumfibrilleren0
—55.871Leerstoornis14
198149.201voltooide zelfmoord24
195547.736Verbetering van reeds bestaande aandoening47
201146.910Virale mutatie geïdentificeerd5
200144.739Verbetering van reeds bestaande aandoening46
201237.628urine-incontinentie0
198137.190voltooide zelfmoord0
197237.185chronische nierziekte44
—34.483Verbetering van reeds bestaande aandoening12
198234.050atriumfibrilleren15
197233.218chronische nierziekte11
200733.035Bradycardie7
199425.624Vochtophoping6
198424.178lage bloedsuiker4
197422.513Stoornis in temperatuurregulatie100
199921.059uitgezaaide borstkanker2
199920.653glioblastoom0
198919.859verworven lipodystrofie0
199119.328Oogpijn17
196718.910overgevoeligheid voor medicijn14
199718.237Restless legs syndroom13
199216.314accidentele vergiftiging0
195215.902Paradoxale reactie op medicijn3
200415.305verhoogde triglyceriden in het bloed3
—13.982migraine0
200313.824dementie7
—13.716voedselallergie0
196413.177chronische nierziekte0
198412.988baby met laag geboortegewicht20
197312.193roodheid17
199111.134Vasculitis4
197311.040ernstige nierziekte0
—10.538migraine0
199410.007Huidkloofjes23
—8.434verhoogde intraoculaire druk0
19957.843neurologische complicatie na narcose3
—7.700doodgeboorte1
19937.469amaurosis fugax4
19977.285hypoglykemisch coma2
20057.280Beginnende slapeloosheid0
—7.035chronische nierziekte0
19936.619psoriasis6
19916.351chronische nierziekte3
19926.276Perforatie van een duodenale zweer2
—6.066perifeer oedeem0
19855.377restant van product aanwezig2
—5.103verlengde QRS-complex op ECG2
19964.791verlies van gevoel0
19844.229amaurosis fugax0
20014.152tic0
—4.056diabetes type 20
19413.863longvaatontsteking2
19953.794hypoglykemisch coma4
19593.533Ademhalingsstilstand4
—3.478Spierletsel6
19973.404afwijkend volledig bloedbeeld1
19843.286Glazige troebelingen5
20013.156complicatie van sedatie2
—2.853verstopping0
19732.245Huidzweer1
—2.169duizeligheid0
20011.632complicatie van sedatie0
19581.575nefrogene anemie0
19791.448keelontsteking0
—784mondontsteking0
Recall-geschiedenis · 50 geregistreerd
DatumKlasseRedenBedrijf
2 jun 2026IIIPresence of foreign substanceANI Pharmaceuticals, Inc.
29 mei 2026IIFailed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.Golden State Medical Supply Inc.
27 mei 2026IIFailed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.Lannett Company Inc.
29 apr 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
29 apr 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
9 apr 2026IIFailed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.The Harvard Drug Group LLC
20 mrt 2026IICGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.Leading Pharma, LLC
10 jan 2026IIPresence of Foreign SubstanceGraviti Pharmaceuticals Private Limited
26 nov 2025IIIFailed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.SUN PHARMACEUTICAL INDUSTRIES INC
18 nov 2025IIICross Contamination with Other ProductsGlenmark Pharmaceuticals Inc., USA
20 okt 2025IIFailed Dissolution SpecificationsGolden State Medical Supply Inc.
10 okt 2025IIFailed Dissolution SpecificationsLannett Company Inc.
10 okt 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
10 okt 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
19 sep 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sep 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sep 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sep 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
3 sep 2025IIFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA
19 jun 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
19 jun 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
27 mei 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
27 mei 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
22 apr 2025IICGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.RemedyRePack Inc.
18 apr 2025IIcGMP DeviationsPreferred Pharmaceuticals, Inc.
24 mrt 2025IICGMP DeviationsRemedyRepack Inc.
17 mrt 2025IIFailed dissolution specifications: lower than specificationsBIOCON PHARMA INC
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mrt 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
4 mrt 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
4 mrt 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
17 feb 2025IIDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC
27 dec 2024IIPresence of Particulate Matter: A market complaint was received of a glass piece in the vial.Eugia US LLC
17 dec 2024IIFailed Dissolution Specifications:Amerisource Health Services LLC
6 dec 2024IICGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.Aurobindo Pharma USA Inc
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
31 okt 2024IIDefective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).Noven Pharmaceuticals Inc
24 sep 2024IIPresence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.Nivagen Pharmaceuticals Inc
31 jul 2024IIPresence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin TabletsGranules Pharmaceuticals Inc.
26 jul 2024IIPresence of Particulate Matter: Complaint received of a glass particle in the vial.Eugia US LLC

Class I = redelijke kans op ernstige schade · Class II = tijdelijk of omkeerbaar · Class III = onwaarschijnlijk schadelijk.

Registratiestatus

Sommige producten van Bryant Ranch Prepack zijn niet FDA-geregistreerd voor humaan gebruik. Voor ongeregistreerde stoffen (peptiden, SARMs zonder humane registratie) bestaat geen legitieme leverancier voor humaan gebruik. Het ontbreken van een inkooproute is de veiligheidsinformatie.